Tag - LTRN

Developments

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Lantern Pharma (NASDAQ: LTRN) and its subsidiary, closely held Starlight Therapeutics, have announced FDA clearance of the investigational new drug (IND) application for STAR-001, in a planned Phase 1 pediatric clinical...

March 27, 2026

Uncategorized

Lantern launches AI center in India to industrialize RADR

Lantern Pharma (NASDAQ: LTRN) has announced the establishment of the AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India, to industrialize its proprietary RADR AI platform, which integrates hundreds of...

January 12, 2026

Feature

Lantern Pharma applying AI to discover and develop cancer therapeutics

Lantern Pharma (NASDAQ:LTRN) is using its RADR AI platform to identify abandoned drug candidates and develop new drugs that may prove effective in treating certain cancers.

October 13, 2020

Tag - LTRN

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Lantern launches AI center in India to industrialize RADR

Lantern Pharma applying AI to discover and develop cancer therapeutics

Subscribe